Momenta Pharmaceuticals, Inc. (MNTA)

[Boing x 2]

Pre Grant MODIFIED GLYCOPROTEINS


http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta


0210] In another aspect, the invention features a sulfated version of abciximab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of adalimumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of alemtuzumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of basiliximab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of bevacizumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of cetuximab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of certolizumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of daclizumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of eculizumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of efalizumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of gemtuzumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of ibritumomab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of infliximab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of muromonab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of natalizumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of omalizumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of palivizumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of panitumumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of ranibizumab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of rituximab comprising a sulfated Fc region or sulfated Fc fragment, a sulfated version of tositumomab comprising a sulfated Fc region or sulfated Fc fragment, or a sulfated version of trastuzumab comprising a sulfated Fc region or sulfated Fc fragment.

[0211] In another aspect, the invention features a sulfated version of abciximab comprising a sulfated glycan, a sulfated version of adalimumab comprising a sulfated glycan, a sulfated version of alemtuzumab comprising a sulfated glycan, a sulfated version of basiliximab comprising a sulfated glycan, a sulfated version of bevacizumab comprising a sulfated glycan, a sulfated version of cetuximab comprising a sulfated glycan, a sulfated version of certolizumab comprising a sulfated glycan, a sulfated version of daclizumab comprising a sulfated glycan, a sulfated version of eculizumab comprising a sulfated glycan, a sulfated version of efalizumab comprising a sulfated glycan, a sulfated version of gemtuzumab comprising a sulfated glycan, a sulfated version of ibritumomab comprising a sulfated glycan, a sulfated version of infliximab comprising a sulfated glycan, a sulfated version of muromonab comprising a sulfated glycan, a sulfated version of natalizumab comprising a sulfated glycan, a sulfated version of omalizumab comprising a sulfated glycan, a sulfated version of palivizumab comprising a sulfated glycan, a sulfated version of panitumumab comprising a sulfated glycan, a sulfated version of ranibizumab comprising a sulfated glycan, a sulfated version of rituximab comprising a sulfated glycan, a sulfated version of tositumomab comprising a sulfated glycan, or a sulfated version of trastuzumab comprising a sulfated glycan.


Boing X 2